All In Biotech

NDA 021450 · Amneal

Zomig

Zolmitriptan · Nasal · Serotonin-1b and Serotonin-1d Receptor Agonist

Last checked: Nov 20, 2026Latest source record: Dec 21, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2003

Sep 30, 2003

Approved uses

4

Original approval plus efficacy supplements

Registered trials

22

7 Phase 3, 0 recruiting

FAERS reports

7,229

4,645 serious, 172 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 30, 2019.

ZOLMITRIPTAN NASAL SPRAY is indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older. Limitations of Use Only use ZOLMITRIPTAN NASAL SPRAY if a clear diagnosis of migraine has been established. If a patient has no response to ZOLMITRIPTAN NASAL SPRAY treatment for the first migraine attack, reconsider the diagnosis of migraine before ZOLMITRIPTAN NASAL SPRAY is administered to treat any subsequent attacks. ZOLMITRIPTAN NASAL SPRAY is not indicated for the prevention of migraine attacks. Safety and effectiveness of ZOLMITRIPTAN NASAL SPRAY have not been established for cluster headache. Not recommended in patients with moderate or severe hepatic impairment [see Dosage and Administration (2.2) ] . ZOLMITRIPTAN NASAL SPRAY is a serotonin (5-HT) 1B/1D receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years and older (1) Limitations of Use: Use only after a clear diagnosis of migraine has been established (1) Not intended for the prophylactic therapy of migraine (1) Not indicated for the treatment of cluster headache (1) Not recommended in patients with moderate to severe hepatic impairment (1)

Mechanism: Zolmitriptan binds with high affinity to human recombinant 5-HT 1D and 5-HT 1B receptors, and moderate affinity for 5-HT 1A receptors. The N-desmethyl metabolite also has high affinity for 5-HT 1B/1D and moderate affinity for 5-HT1A receptors. Current theories proposed to explain the etiology of migraine headache suggest that symptoms are due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of zolmitriptan for...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • ZOMIG · ZOLMITRIPTAN 5MG/SPRAY · SPRAY, NASAL · Prescription · TE AB
  • ZOMIG · ZOLMITRIPTAN 2.5MG/SPRAY · SPRAY, NASAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Zolmitriptan" as an intervention, any sponsor and status, largest first.

All 22 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • migraine1,032
  • headache954
  • drug ineffective755
  • nausea559
  • off label use558
  • fatigue485
  • pain431
  • drug intolerance367
  • vomiting348
  • dizziness339
  • malaise301
  • dyspnoea290

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004116
2005112
2006120
2007154
2008166
2009176
2010207
2011348
2012658
2013224
2014267
2015259
2016407
2017386
2018388
2019528
2020477
2021400
2022377
2023383
2024396
2025390
2026290

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zomig* (Zolmitriptan)

2024 spending

$255K

Beneficiaries

90

202 claims

Per beneficiary

$2,829

$93.86 per unit

View as table
YearSpending
2020$9,491,165
2021$6,361,555
2022$2,963,029
2023$1,272,976
2024$254,577

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 163 on PubMed

Sponsor: Amneal

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.